<h2>Switching from other basal insulins to Toujeo® (Insulin Glargine)</h2>

TYPE-2-DIABETES

DIABETES

DOWNLOAD OUR BROCHURE WITH PRACTICAL DOSE ADVICE

<h2>How to switch from other basal insulins to Toujeo®1,2</h2>

Toujeo DoubleStar®&nbsp;this pen has 900 units3&nbsp;and up to 160 units in one injection2.

The&nbsp;Toujeo SoloStar®&nbsp;pen has 450 units2&nbsp;and up to 80 units in one injection2.

<h2>Switching from Glargine 100 (e.g. Lantus®) to Glargine 300 (e.g. Toujeo®)</h2>

<h2>Switching from NPH/other basal insulin (e.g. Insulatard) to Toujeo®</h2>
When switching from NPH insulin to Toujeo®, the starting dose depends on whether the patient has taken the NPH insulin once or twice a day.&nbsp;

For example, if the person has taken 2 x 40 U Insulatard = 80 U, they should start with a dose of 64 U Toujeo®&nbsp;once a day.&nbsp;

<h2>With Toujeo®, you can effectively titrate your patients to the target of 4.5-6.0 mmol/L1</h2>
The dose is adjusted every 7 days,&nbsp;based on the median of the patient's last 3 fasting blood glucose measurements.
The titration algorithm is for illustrative use and&nbsp;adaptation with regard to the individual and goal of treatment is necessary.

<ol>
 <li>
 Rosenstock J, Cheng A, Ritzel R et al. More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naïve type 2 diabetes: the randomized head-to-head BRIGHT trial. Diabetes Care 2018 Oct; 41(10): 2147-2154 2. Toujeo SPC 08.2024.</li>
</ol>
TOUJEO® (insulin glargine 300 units/ml) – Abbreviated Prescribing Information
NAME AND PRESENTATION: Toujeo 300 units/ml SoloStar, solution for injection in a prefilled pen. Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen. 1 ml of solution contains 300 units of insulin glargine. Each SoloStar prefilled pen contains 1,5 ml of solution for injection (equivalent to 450 units). Each DoubleStar pen contains 3 ml of solution for injection (equivalent to 900 units). THERAPEUTIC INDICATIONS: Treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years. POSOLOGY AND METHOD OF ADMINISTRATION*: Toujeo is a basal insulin for once-daily administration at any time of the day, preferably at the same time every day. When needed, patients can administer Toujeo up to 3 hours before or after their usually time of administration. The dose regimen (dose and timing) should be adjusted according to individual response. In type 1 diabetes mellitus, Toujeo is to be used once-daily and must be combined with short-/rapid-action insulin to cover mealtime insulin requirements. In patients with type 2 diabetes mellitus, the recommended daily starting dose is 0.2 units/kg. Toujeo can also be given together with other anti-hyperglycaemic medicinal products. Switch: When switching from insulin glargine 100 units/ml to Toujeo, this can be done on a unit-to-unit basis. When switching from a treatment regimen with an intermediate or long-action insulin to a regimen with Toujeo, a change of the dose of the basal insulin may be required and the concomitant anti-hyperglycaemic treatment may need to be adjusted. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. For switch details see full SmPC. Special populations: Toujeo can be used in elderly people, renal and hepatic impaired patients and adolescents and children ≥6 years. Renal impairment &amp; hepatic impairment: insulin requirements may be diminished. Elderly: progressive deterioration of a renal function may lead to a steady decrease in insulin requirements. Children: Toujeo can be used in in adolescents and children based on the same principles as adult patients. When switching to Toujeo, dose reduction on basal and bolus insulins needs to be considered on an individual basis to minimize risk of hypoglycaemia. Safety and efficacy in children below 6 years have not been established, no data are available. Method of administration: For subcutaneous use only. Rotate injection sites to reduce the risk of lipodystrophy and cutaneous amyloidosis. Toujeo must not be administered intravenously or in insulin infusion pumps. The Toujeo SoloStar and Toujeo DoubleStar pre-filled pens have been specifically designed for Toujeo and no dose re-calculation is required for either pen. When changing from Toujeo SoloStar to Toujeo DoubleStar, if the patient’s previous dose was an odd number (e.g. 23 units) then the dose must be increased or decreased by 1 unit (e.g. 24 or 22 units). Toujeo DoubleStar prefilled pen is recommended for patients requiring at least 20 units per day. Toujeo must not be drawn from the cartridge of the Toujeo SoloStar pre-filled pen or Toujeo DoubleStar pre-filled pen into a syringe or severe overdose can result. For administration details see full SmPC. CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients listed in the full SmPC. SPECIAL WARNINGS AND PRECAUTIONS FOR USE*: Record name and batch number of administered product to improve traceability of biological medicinal products. Toujeo is not the insulin of choice for the treatment of diabetic ketoacidosis. Instruct patients to continuously rotate injection site to reduce risk of lipodystrophy and cutaneous amyloidosis; delayed insulin absorption and worsened glycaemic control may occur after injection at affected sites. Sudden change in injection site to unaffected area has resulted in hyperglycaemica; blood glucose monitoring is recommended after changing injection site and dose adjustment of antidiabetic medications may be considered. The prolonged effect of insulin glargine may delay recovery from hypoglycaemia. Insulin glargine 100 units/ml and Toujeo are not bioequivalent and are not interchangeable and switching may result in the need for a change in dose and should only be done under strict medical supervision. Switching patients between other insulins and Toujeo should be done under strict medical supervision and may result in the need for a change in dose. Intercurrent illness requires intensified metabolic monitoring. In rare cases the presence of insulin antibodies may necessitate adjustment of insulin dose. If pioglitazone is used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs. For further details on special warnings and precautions for use see full SmPC. DRUG INTERACTIONS*: Substances that may enhance or reduce the blood glucose-lowering activity and increase susceptibility to hypoglycaemia are detailed in the full SmPC. PREGNANCY AND LACTATION*: There is no clinical experience with use of Toujeo in pregnant women. For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women indicate no specific adverse effects on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. The use of Toujeo may be considered during pregnancy if clinically needed. It is unknown whether insulin glargine is excreted in human milk. No metabolic effects on breast-fed newborn/infant are anticipated as insulin glargine is digested into amino acids in the gastrointestinal tract. EFFECTS ON ABILITY TO DRIVE*: Patient’s ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. UNDESIRABLE EFFECTS*: Very common: Hypoglycemia. Hypoglycaemia may occur if the insulin dose is too high in relation to the insulin requirement. Common: Lipohypertrophy; injection site reactions. For full list of undesirable effects consult the full SmPC. Clinical study safety data not available for children &lt;6 years. OVERDOSAGE*: Mild episodes of hypoglycaemia can usually be treated with oral carbohydrates. More severe episodes may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. PHARMACOLOGICAL PROPERTIES: ATC Code: A10A E04. MARKETING AUTHORIZATION HOLDER: Sanofi-Aventis Deutschland GmbH, D 65926 Frankfurt am Main, Germany. LEGAL CATEGORY: Medicinal product subject to medical prescription. DATE OF LAST REVIEW: Aug 2024
Abbreviated Prescribing information based on the EU SMPC as of Nov 2023.
Before prescribing the product always refer to your full local prescribing information as this information may vey from country to country.
For local details, please refer to below information.
The Netherlands: Aflevering en vergoeding: U.R. Toujeo wordt volledig vergoed. Voor prijzen zie de Z-index taxe. Deze informatie is het laatst herzien in August 2024. Voor meer informatie, zie de geregistreerde productinformatie. Lokale vertegenwoordiger: Sanofi B.V., Paasheuvelweg 25, 1105 BP Amsterdam. Tel: 020 245 4000.

References

Heeft u vragen of wilt u meer weten? Wij zorgen dat u zo snel mogelijk geholpen wordt.

Wij staan klaar

Switching from other basal insulins to Toujeo® (Insulin Glargine)

Voor uw intercontext, meld u aan bij uw account Sanofi Campus. Geef uw e-mail door aan uw e-mail.

Als u onze eerste e-mail op {email} tot bevestig uw account u kunt hieronder een nieuwe aanvragen. Als je het niet ziet, moet je mogelijk je spammap controleren.

Deze informatie wordt alleen gebruikt om uw account te valideren en wordt niet verspreid.

titel

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

Om u een gepersonaliseerde ervaring te bieden, moet u

Je profiel is onvolledig

De ADCT geeft een indicatie van hoe gecontroleerd het eczeem is. Beantwoord deze 6 eenvoudige vragen met uw patiënt om de ADCT-score te vinden. Het zal de juiste handelwijze aangeven.

Atopische dermatitis, een vorm van eczeem, kan het leven van uw patiënt op meer manieren beïnvloeden dan u weet.

Doe de atopische dermatitis controle test (ADCT)

Geniet van meer exclusieve inhoud{newline}door <a>door u vandaag te registreren</a>

Heb je al een account? <a>Hier inloggen</a>

Best practices voor het optimaliseren van de patiëntenzorg

Krijg een aangepast beeld van de onderwerpen waarin u geïnteresseerd bent, samen met de mogelijkheid om inhoud op te slaan om op een later tijdstip te bekijken of te lezen.

Onbeperkte toegang tot eersteklas inhoud, whitepapers, casestudy's, onderzoekspapers, webinars, training en up-to-date wetenschappelijke medische bronnen.

Gepersonaliseerde inhoud op basis van uw interessegebieden

Maak contact en blijf up-to-date met collega's op uw vakgebied en onderwerpen die u interesseren via gratis evenementen en leidinggevende forums.

Registreer om het volledige artikel te lezen.

Wij respecteren uw privacy en zullen uw informatie niet delen met derden.

Actuele gidsen die speciaal voor patiënten zijn geschreven

Onbeperkte toegang tot de nieuwste patiëntengidsen en bronnen. Deel inhoud met uw patiënten met gebruiksvriendelijke online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Beperkte toegang

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

Normaal gesproken bieden we een schat aan kenis, maar we konden niet vinden waar je naar op zoek bent.

We konden niet vinden wat je zocht

Sanofi is niet verantwoordelijk voor de inhoud van deze externe website.

U staat op het punt Campus.sanofi/nl te verlaten.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Volg ons:

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een lijst met evenementen en tools en diensten voor uw dagelijkse praktijk.

Bevestig uw status

Welcome to ITP Sanofi Campus

De inhoud van deze website is alleen toegankelijk voor geregistreerde gebruikers.

Log in alstublieft

Email verificatie

U ziet een voorbeeld van de portal. Wis uw cookies (bijvoorbeeld door uw browservenster te sluiten) om terug te gaan naar de openbare modus.

We hebben onze privacyverklaring bijgewerkt om je gegevens beter te beschermen en je ervaring te verbeteren. Neem even de tijd om de wijzigingen door te nemen door <privacyNewTab>hier te klikken</privacyNewTab>. Uw privacy is belangrijk voor ons. Klik op doorgaan om te bevestigen dat u de nieuwe privacyverklaring hebt gelezen.

Update van de privacyverklaring

Communicatie toestemming

My consents

Password

Confirm password

{resultsCount, plural, one {resultaat} other {resultaten}}

Log in om toegang te krijgen tot de resultaten

U moet inloggen op uw account om toegang te krijgen tot medische inhoud.

Inloggen

Registreer in minder dan 1 minuut om toegang te krijgen tot de resultaten

U verlaat nu het Sanofi inhoudsgedeelte van onze site en komt in het inhoudsgedeelte voor extern medisch bibliografisch zoeken.

U verlaat nu het externe medische bibliografische zoekgedeelte van onze site en komt in het inhoudsgedeelte van Sanofi.